Scala Biodesign

Scala Biodesign Overview

Scala Biodesign develops cutting-edge computational protein design solutions to address complex protein development challenges in the pharmaceutical, chemical, diagnostics and food sectors. Antibodies, vaccines and sustainable chemical manufacturing demand proteins that meet exceptionally stringent requirements in activity, shelf-life and safety. Yet, traditional methods for protein engineering are costly, lengthy and failure-prone. Scala’s one-shot approach dramatically accelerates the development process, increases success rates and slashes R&D efforts, thereby enabling its partners to pursue challenging projects that were previously beyond their reach. Scala has partnered with some of the largest pharma and chemical corporations worldwide and its technology has successfully overcome development challenges that confounded expert teams for years. Scala, under the leadership of Dr. Ravit Netzer (CEO) and Dr. Adi Goldenzweig (CTO), leverages the technologies they developed in the group of Prof. Sarel Fleishman (Chief Scientist) which was licensed from the Weizmann Institute of Science. Scala is positioned to become the primary destination for corporations venturing into new protein-based product development.

Cumulative Funding Raised Over Time ($)

Latest News

Sep 11, 2023 · www.calcalistech.com

growth-positive

Scala Biodesign exits stealth with $5.5 million in Seed to engineer future proteins | CTech

Scala Biodesign, a biotech company that accelerates the development of proteins in biotech products, has raised $5.5 million in seed funding led by TLV Partners. The company, an alumnus of the Intel Ignite acceleration program, uses physics-based modeling, AI, and biological data analysis to help companies develop new medicines and foods faster and cheaper. The technology could also enable the creation of new biotechnology applications. The company was founded by Dr. Ravit Netzer, Dr. Adi Goldenzweig, and Prof. Sarel Fleishman to meet the demand from pharma and biotech companies.

Investment

Sep 11, 2023 · techcrunch.com

growth-positive

Scala Biodesign makes it easy to re-engineer proteins one molecule at a time - or 50 | TechCrunch

Scala Biodesign, a biotech company that uses AI to improve the practicality of existing or promising drugs, has raised $5.5 million in seed funding led by TLV partners. The company, which was spun out of research done at the Weizmann Institute of Science in Tel Aviv, uses AI to predict the 3D structure and behavior of proteins, which can help to accelerate the process of engineering therapeutic molecules. Scala is currently working with unnamed pharmaceutical companies and labs, and plans to use the funding to pursue more partnerships and studies.

Investment

Funding

Team Members

2

Employees: 11-50

Web & Social Links

Locations

Menachem Begin St 156, Tel Aviv-Yafo, 6492108, Israel

Photos & Videos

No files yet

Scala Biodesign Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info